Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Influential Role of BCL2 Family Members in Synovial Sarcomagenesis.
Barrott JJ, Zhu JF, Smith-Fry K, Susko AM, Nollner D, Burrell LD, Pozner A, Capecchi MR, Yap JT, Cannon-Albright LA, Deng X, Jones KB. Barrott JJ, et al. Among authors: yap jt. Mol Cancer Res. 2017 Dec;15(12):1733-1740. doi: 10.1158/1541-7786.MCR-17-0315. Epub 2017 Aug 29. Mol Cancer Res. 2017. PMID: 28851813 Free PMC article.
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M. Kinsey CG, et al. Among authors: yap jt. Nat Med. 2019 Apr;25(4):620-627. doi: 10.1038/s41591-019-0367-9. Epub 2019 Mar 4. Nat Med. 2019. PMID: 30833748 Free PMC article.
Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M. Kinsey CG, et al. Among authors: yap jt. Nat Med. 2019 May;25(5):861. doi: 10.1038/s41591-019-0433-3. Nat Med. 2019. PMID: 30918364
Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.
von Mehren M, George S, Heinrich MC, Schuetze SM, Yap JT, Yu JQ, Abbott A, Litwin S, Crowley J, Belinsky M, Janeway KA, Hornick JL, Flieder DB, Chugh R, Rink L, Van den Abbeele AD. von Mehren M, et al. Among authors: yap jt. Clin Cancer Res. 2020 Apr 15;26(8):1837-1845. doi: 10.1158/1078-0432.CCR-19-1069. Epub 2019 Dec 2. Clin Cancer Res. 2020. PMID: 31792037 Free PMC article. Clinical Trial.
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S. Ben-Ami E, et al. Among authors: yap jt. Ann Oncol. 2016 Sep;27(9):1794-9. doi: 10.1093/annonc/mdw228. Epub 2016 Jul 1. Ann Oncol. 2016. PMID: 27371698 Free PMC article. Clinical Trial.
49 results